SII will develop and manufacture the vaccine, as per the agreement
Cipla has signed an exclusive pact with Serum Institute of India (SII) to market flu vaccine, Nasovac-S, in the country. As per the agreement, SII will develop and manufacture the vaccine, and Cipla will exclusively market it in India.
"We are extremely delighted to have entered into a strategic partnership with SII in India. This collaboration is aligned with our commitment to access to affordable healthcare. This partnership is a significant step towards making preventative healthcare accessible to a large number of Indians through Cipla's strong countrywide sales force," said Mr Subhanu Saxena, managing director and global chief executive officer, Cipla, in a statement.
Having initiated the approval process with the European Medicines Authority for marketing the products developed and manufactured by SII, Cipla is now forging ahead looking at other markets where the company has a strong presence.